Varun Saxena, Vandana Khungar, Elizabeth C. Verna, Josh Levitsky, Robert S. Brown, Mohamed A. Hassan, Mark S. Sulkowski, Jacqueline G. O'Leary, Farrukh Koraishy, Joseph S. Galati, Alexander A. Kuo, Monika Vainorius, Lucy Akushevich, David R. Nelson, Michael W. Fried, Norah Terrault, K. Rajender Reddy – 15 May 2017 – Data outside of clinical trials with direct‐acting antiviral regimens with or without ribavirin as treatment of chronic hepatitis C virus in solid organ transplant recipients are limited.

Quan‐Yu Zhang, Ling‐Ping Zhao, Xiao‐Xiang Tian, Cheng‐Hui Yan, Yang Li, Yan‐Xia Liu, Pi‐Xiao Wang, Xiao‐Jing Zhang, Ya‐Ling Han – 15 May 2017 – Cellular repressor of E1A‐stimulated genes (CREG), a novel cellular glycoprotein, has been identified as a suppressor of various cardiovascular diseases because of its capacity to reduce hyperplasia, maintain vascular homeostasis, and promote endothelial restoration. However, the effects and mechanism of CREG in metabolic disorder and hepatic steatosis remain unknown.

Michael Zimmer, Pradeep Bista, Ericka L. Benson, Diana Y. Lee, Feng Liu, Dominic Picarella, Rick B. Vega, Chi B. Vu, Maisy Yeager, Min Ding, Guosheng Liang, Jay D. Horton, Robert Kleemann, Teake Kooistra, Martine C. Morrison, Peter Y. Wielinga, Jill C. Milne, Michael R. Jirousek, Andrew J. Nichols – 12 May 2017 – CAT‐2003 is a novel conjugate of eicosapentaenoic acid (EPA) and niacin designed to be hydrolyzed by fatty acid amide hydrolase to release EPA inside cells at the endoplasmic reticulum.

Romain Désert, Florian Rohart, Frédéric Canal, Marie Sicard, Mireille Desille, Stéphanie Renaud, Bruno Turlin, Pascale Bellaud, Christine Perret, Bruno Clément, Kim‐Anh Lê Cao, Orlando Musso – 12 May 2017 – Hepatocellular carcinomas (HCCs) exhibit a diversity of molecular phenotypes, raising major challenges in clinical management. HCCs detected by surveillance programs at an early stage are candidates for potentially curative therapies (local ablation, resection, or transplantation). In the long term, transplantation provides the lowest recurrence rates.

Edward J. Gane, Mitchell L. Shiffman, Kyle Etzkorn, Giuseppe Morelli, Catherine A.M. Stedman, Mitchell N. Davis, Federico Hinestrosa, Hadas Dvory‐Sobol, K.C. Huang, Anu Osinusi, John McNally, Diana M. Brainard, John G. McHutchison, Alex J. Thompson, Mark S. Sulkowski, GS‐US‐342‐1553 Investigators – 12 May 2017 – The optimal retreatment strategy for patients chronically infected with hepatitis C virus who experience virologic failure after treatment with direct‐acting antiviral–based therapies remains unclear.

Sarah M. Ordway, Manish B. Singla, Patrick E. Young, Rohit Satoskar, Ryan M. Kwok – 12 May 2017 – Despite an unmet need for hepatologists in the United States, every year transplant hepatology (TH) fellowship positions remain unfilled. To address this, we investigated factors that influence trainee decisions about pursuing a career in hepatology.

Davor Slijepcevic, Reinout L.P. Roscam Abbing, Takeshi Katafuchi, Antje Blank, Joanne M. Donkers, Stéphanie van Hoppe, Dirk. R. de Waart, Dagmar Tolenaars, Jonathan H.M. van der Meer, Manon Wildenberg, Ulrich Beuers, Ronald P.J. Oude Elferink, Alfred H. Schinkel, Stan F.J. van de Graaf – 12 May 2017 – The Na+‐taurocholate cotransporting polypeptide (NTCP/SLC10A1) is believed to be pivotal for hepatic uptake of conjugated bile acids. However, plasma bile acid levels are normal in a subset of NTCP knockout mice and in mice treated with myrcludex B, a specific NTCP inhibitor.

Jeffrey B. Schwimmer, Cynthia Behling, Jorge Eduardo Angeles, Melissa Paiz, Janis Durelle, Jonathan Africa, Kimberly P. Newton, Elizabeth M. Brunt, Joel E. Lavine, Stephanie H. Abrams, Prakash Masand, Rajesh Krishnamurthy, Kelvin Wong, Richard L. Ehman, Meng Yin, Kevin J. Glaser, Bogdan Dzyubak, Tanya Wolfson, Anthony C. Gamst, Jonathan Hooker, William Haufe, Alexandra Schlein, Gavin Hamilton, Michael S. Middleton, Claude B.

Jeffrey B. Schwimmer, Cynthia Behling, Jorge Eduardo Angeles, Melissa Paiz, Janis Durelle, Jonathan Africa, Kimberly P. Newton, Elizabeth M. Brunt, Joel E. Lavine, Stephanie H. Abrams, Prakash Masand, Rajesh Krishnamurthy, Kelvin Wong, Richard L. Ehman, Meng Yin, Kevin J. Glaser, Bogdan Dzyubak, Tanya Wolfson, Anthony C. Gamst, Jonathan Hooker, William Haufe, Alexandra Schlein, Gavin Hamilton, Michael S. Middleton, Claude B.

Benedetta Terziroli Beretta‐Piccoli, Giorgina Mieli‐Vergani, Raffaela Bertoli, Luca Mazzucchelli, Charity Nofziger, Markus Paulmichl, Diego Vergani – 8 May 2017 – We report a novel association between the commonly used antimalarial medication atovaquone/proguanil and drug‐induced autoimmune‐like hepatitis. The patient developed severe liver disease fulfilling biochemical, immunologic, and histologic criteria for the diagnosis of autoimmune hepatitis after the inadvertent rechallenge with the offending drug, which had caused self‐limited hepatitic symptoms a year previously.